Medicus Pharma (NASDAQ:MDCX) Raised to Sell at Wall Street Zen

Medicus Pharma (NASDAQ:MDCX) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

MDCX has been the subject of a number of other research reports. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Weiss Ratings raised shares of Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $450.00.

Medicus Pharma Trading Down 12.6%

Shares of Medicus Pharma stock opened at $1.88 on Friday. Medicus Pharma has a 52 week low of $1.82 and a 52 week high of $127.50. The stock has a market cap of $2.37 million, a PE ratio of -0.02 and a beta of 0.30. The company’s 50-day moving average price is $7.27 and its two-hundred day moving average price is $23.43.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($10.50) earnings per share for the quarter, missing the consensus estimate of ($6.38) by ($4.12). On average, equities analysts predict that Medicus Pharma will post -36.25 EPS for the current fiscal year.

Institutional Trading of Medicus Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in MDCX. Interchange Capital Partners LLC boosted its stake in Medicus Pharma by 33.9% in the third quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock valued at $343,000 after acquiring an additional 538,039 shares during the last quarter. Sterling Investment Advisors Ltd. bought a new stake in shares of Medicus Pharma in the second quarter worth about $45,000. Finally, Private Advisor Group LLC raised its holdings in Medicus Pharma by 36.8% during the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after buying an additional 64,560 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.